Novel Diagnostic Methods for Imaging Amyloid Beta in the eye in association with alzheimer's disease

对于阿尔茨海默病(AD)，目前还没有广泛可用的治愈和早期检测方法。只有在死后才能确诊。广告对个人健康有很大的负面影响，给社会带来了巨大的成本。早期诊断和改进的疾病跟踪导致更早和更好的治疗。在AD早期，淀粉样β蛋白在大脑中形成沉积。我们将开发一种更简单的方法来成像眼睛后面活的神经组织中的淀粉样β沉积。坎贝尔的研究小组已经证明，这些沉积物应该足够大，可以在眼睛的图像中检测到。然后，它们可以用来诊断和监测AD的恶化阶段。我们将探索视网膜中的淀粉样β蛋白与AD严重程度之间的关系。视网膜中的淀粉样β蛋白沉积将在死亡后进行评估。我们将描述视网膜沉积物的位置、密度、大小和形状。在另一项UBC研究中，AD的分期将在临终前在诊所进行测量。他们的

There is no cure and no early detection method broadly available for Alzheimer's disease (AD). Definite diagnosis is only after death. AD has a large negative impact on individual health and an enormous cost to society. Early diagnosis and improved disease tracking lead to earlier and better treatment. Amyloid beta forms deposits in the brain early in AD. We will develop a simpler method to image amyloid beta deposits in the living neural tissue at the back of the eye. Campbell's group has shown that these deposits should be large enough to be detected in images of the eye. They could then be used to diagnose and monitor the worsening stages of AD. We will explore the association between amyloid beta in the retina and the severity of AD. Amyloid beta deposits in retinas will be assessed after death. We will characterize the location, density, size and shape of retinal deposits. In a separate UBC study, the stage of AD will be measured in the clinic before death. Their